DK2054443T3 - Antistoffer mod en epitop fra AGR2, assays og hybridomer - Google Patents

Antistoffer mod en epitop fra AGR2, assays og hybridomer

Info

Publication number
DK2054443T3
DK2054443T3 DK07789322.0T DK07789322T DK2054443T3 DK 2054443 T3 DK2054443 T3 DK 2054443T3 DK 07789322 T DK07789322 T DK 07789322T DK 2054443 T3 DK2054443 T3 DK 2054443T3
Authority
DK
Denmark
Prior art keywords
antibodies
agr2
epitope
hybridomas
assays
Prior art date
Application number
DK07789322.0T
Other languages
English (en)
Inventor
Roger Barraclough
Dong Liu Barraclough
Philip Rudland
Original Assignee
Univ Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liverpool filed Critical Univ Liverpool
Application granted granted Critical
Publication of DK2054443T3 publication Critical patent/DK2054443T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
DK07789322.0T 2006-08-26 2007-08-28 Antistoffer mod en epitop fra AGR2, assays og hybridomer DK2054443T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0616929.6A GB0616929D0 (en) 2006-08-26 2006-08-26 Antibodies, assays and hybridomas
PCT/GB2007/003235 WO2008025964A2 (en) 2006-08-26 2007-08-28 Antibodies to an epitope of agr2. assays and hybridomas

Publications (1)

Publication Number Publication Date
DK2054443T3 true DK2054443T3 (da) 2010-11-15

Family

ID=37102874

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07789322.0T DK2054443T3 (da) 2006-08-26 2007-08-28 Antistoffer mod en epitop fra AGR2, assays og hybridomer

Country Status (11)

Country Link
US (1) US8329875B2 (da)
EP (1) EP2054443B1 (da)
AT (1) ATE474857T1 (da)
AU (1) AU2007291077B2 (da)
CA (1) CA2661803A1 (da)
DE (1) DE602007007958D1 (da)
DK (1) DK2054443T3 (da)
ES (1) ES2351801T3 (da)
GB (1) GB0616929D0 (da)
PT (1) PT2054443E (da)
WO (1) WO2008025964A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100983386B1 (ko) * 2008-09-12 2010-09-20 성균관대학교산학협력단 난소암 진단을 위한 ａｇｒ-2의 신규한 용도
CN101519649B (zh) * 2009-01-22 2010-11-03 上海交通大学 杂交瘤细胞株及其制备方法
US9415088B2 (en) 2011-02-25 2016-08-16 The Board Of Trustees Of The Leland Stanford Junior University Use of AGR3 for treating cancer
CN102268089A (zh) * 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
WO2013040358A2 (en) * 2011-09-14 2013-03-21 University Of Washington Through Its Center For Commercialization Assays and compositions for detection of agr2
US10428159B2 (en) * 2014-09-09 2019-10-01 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
CN109576229A (zh) * 2018-12-13 2019-04-05 华中科技大学同济医学院附属协和医院 一种分泌抗agr2的单克隆抗体杂交瘤细胞株及其应用
CN113336853B (zh) * 2020-11-04 2022-06-14 华中科技大学同济医学院附属协和医院 针对agr3蛋白的单克隆抗体、制备方法及其应用
US20240118281A1 (en) * 2021-01-11 2024-04-11 University Of Florida Research Foundation, Incorporated Anticancer compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319089A1 (en) * 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
US20040141974A1 (en) * 2000-02-25 2004-07-22 Boyd Robert Simon Diagnostic and therapeutic methods
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
AU2003209459A1 (en) * 2002-03-06 2003-09-16 Hybrigenics Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
WO2004044178A2 (en) * 2002-11-13 2004-05-27 Genentech, Inc. Methods and compositions for diagnosing dysplasia
ES2299281B1 (es) 2003-10-22 2009-04-16 Progenika Biopharma, S.A. Metodos para el diagnostico in vitro y pronostico in vitro del cancer de pancreas, y para el desarrollo de farmacos contra el cancer de pancreas.

Also Published As

Publication number Publication date
US20110052586A1 (en) 2011-03-03
EP2054443B1 (en) 2010-07-21
ES2351801T3 (es) 2011-02-10
CA2661803A1 (en) 2008-03-06
GB0616929D0 (en) 2006-10-04
US8329875B2 (en) 2012-12-11
AU2007291077B2 (en) 2012-03-08
AU2007291077A1 (en) 2008-03-06
DE602007007958D1 (de) 2010-09-02
WO2008025964A2 (en) 2008-03-06
EP2054443A2 (en) 2009-05-06
ATE474857T1 (de) 2010-08-15
PT2054443E (pt) 2010-10-26
WO2008025964A3 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
DK2054443T3 (da) Antistoffer mod en epitop fra AGR2, assays og hybridomer
ATE509033T1 (de) Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
MX2009009450A (es) Anticuerpos monoclonales para he4 y metodos para su uso.
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
JP2017518366A5 (da)
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
ATE551367T1 (de) Epha2-bindende antikörper und verfahren zu ihrer verwendung
EA201100231A1 (ru) Диагностический анализ на основе антител
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
JP2015533788A5 (da)
JP2010518847A5 (da)
BRPI0410261B8 (pt) anticorpo monoclonal que se liga especificamente ao probnp, métodos para detecção específica de probnp in vitro e para diagnóstico de insuficiência cardíaca in vitro, kit para medição de probnp, e linhagem celular de hibridoma mab 1.21.3
EP1708745A4 (en) ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE
DE502005010086D1 (de) Monoklonaler antikörper gegen humanen frizzled-4-rezeptor
US20110177525A1 (en) Antibodies and methods of diagnosing diseases
WO2012112013A3 (en) A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer
JP2012503634A5 (da)
DE602005022757D1 (de) Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
DE602006018458D1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
WO2012165926A3 (ko) 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2006060188A3 (en) Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
DE602006020467D1 (de) Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
JP2012521745A5 (da)
ATE512671T1 (de) Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs